Cephalic tetanus is a rare variant of localized tetanus (accounting for 1–3% of all tetanus cases) confined to the head and neck, characterized by trismus, dysphagia, and cranial nerve palsies — most commonly CN VII — following head or neck wounds. [1-3] Diagnosis is often delayed and outcomes are poor due to the high risk of progression to generalized tetanus and cardiorespiratory compromise. [2][4]
1. History
- Port of entry: Ask specifically about recent head trauma, facial lacerations, dental procedures, ear infections (otitis media), and eye injuries [1-2]
- Incubation period: Typically 3–21 days from injury to first symptom; shorter incubation (<7 days) portends worse prognosis [1]
- Period of onset: Time from first symptom to first spasm — ≤48 hours suggests severe disease [5]
- Symptom characterization: Jaw stiffness/difficulty opening mouth, facial weakness (unilateral or bilateral), difficulty swallowing, painful spasms of the lower face and neck, voice changes [1-2]
- Vaccination history: Number of tetanus toxoid doses, date of last booster — unknown or incomplete history should be treated as unvaccinated [6]
- Important negatives: Preserved consciousness (lucidity is maintained in tetanus, unlike many neurological infections); no sensory deficits; no altered mental status [2]
2. Alarm Features
- Progression to generalized tetanus: New truncal rigidity, opisthotonus, or limb spasms beyond the head/neck [1-2]
- Airway compromise: Laryngeal or pharyngeal spasm, stridor, apneic spells, dyspnea [1-2]
- Aspiration risk: Severe dysphagia with inability to manage secretions [2]
- Autonomic dysfunction: Labile blood pressure, tachycardia alternating with bradycardia, profuse sweating, fever — most feared complication and leading cause of death in ventilated patients [2]
- Respiratory failure: Can occur rapidly even without generalized tetanus, as toxin spreads among brainstem nuclei affecting respiratory centers [4]
3. Medications
- Antibiotics: Metronidazole 500 mg IV q6–8h for 7–10 days (first-line); penicillin is an alternative but theoretically may potentiate tetanus neurotoxin effects via GABA-A antagonism [1-2]
- Antitoxin: Human tetanus immunoglobulin (HTIG) 500 IU IM (single dose); equine antitoxin if HTIG unavailable [1][7]
- Active immunization: Td or Tdap 0.5 mL IM at a different site from HTIG — tetanus does not confer natural immunity [1-2]
- Spasm control: IV benzodiazepines (diazepam 10–30 mg IV q1–4h PRN); propofol as second-line; neuromuscular blocking agents (vecuronium preferred over pancuronium) for refractory spasms [1]
- Autonomic dysfunction: Magnesium sulfate or labetalol for sympathetic hyperactivity [1]
- Contraindicated/caution: Avoid pancuronium (worsens autonomic instability); use penicillin with awareness of theoretical GABA antagonism [1]
4. Diet
- NPO initially if significant trismus or dysphagia — high aspiration risk
- Enteral feeding via soft, small-bore nasogastric tube or parenteral nutrition via central venous catheter when oral intake is not possible [1]
- Hydration: Aggressive IV fluid management, especially with rhabdomyolysis risk from sustained spasms
- Long-term: Resume oral diet only when swallowing function is confirmed safe
5. Review of Systems
- Neurologic: Jaw stiffness, facial weakness, difficulty speaking, eye deviation, eyelid retraction, neck stiffness [1]
- Respiratory: Dyspnea, stridor, apneic episodes, cough with swallowing (aspiration)
- GI: Dysphagia, reduced oral intake, abdominal rigidity (if generalizing)
- Cardiovascular: Palpitations, chest pain (Takotsubo cardiomyopathy is the most common cardiovascular complication) [1][8]
- GU: Urinary retention (autonomic dysfunction) [2]
- MSK: Back pain, muscle stiffness (signs of generalization)
6. Collateral History and Family History
- Collateral: Witnesses to the injury mechanism; timeline of symptom onset; vaccination records from primary care or military service (military service since 1941 implies at least one dose) [9]
- Social context: Occupation (farming, gardening), rural residence, injection drug use — all increase risk [2][10]
- Immigration/travel: Origin from or travel to regions with low vaccination coverage (South/Southeast Asia, sub-Saharan Africa) [2]
- Family history: Not directly relevant (tetanus is not hereditary), but household vaccination status may reflect shared under-immunization
7. Risk Factors
- Incomplete or absent vaccination — the single most important risk factor; 43.9% of US tetanus cases had received zero doses [10]
- Older age and male sex [2][10]
- Head/neck wounds: Lacerations, penetrating injuries, dental procedures, chronic otitis media, eye injuries [1-2]
- Immunosuppression: HIV, immunosuppressive therapy — these patients should receive HTIG regardless of vaccination history [1][6]
- Rural residence, farming, gardening injuries [2][11]
- Injection drug use [2]
- Wound characteristics: Contamination with dirt/soil/feces, devitalized tissue, puncture wounds, delayed wound care [1]
8. Differential Diagnosis
The differential for cephalic tetanus specifically includes: [2]
- Bell palsy: Isolated facial weakness without trismus; no history of wound; no spasms
- Brainstem stroke / TIA: Symptoms may fluctuate in cephalic tetanus mimicking TIA; stroke will show imaging abnormalities; tetanus preserves consciousness [2]
- Botulism: Descending flaccid paralysis, bilateral, with pupillary involvement; no trismus or rigidity; rapid onset
- Myasthenia gravis: Fatigable weakness, no trismus, positive antibodies
- Peritonsillar/retropharyngeal abscess: Trismus present but with fever, sore throat, and visible oropharyngeal pathology
- Strychnine poisoning: Virtually indistinguishable from tetanus but rapid onset (<30 min of ingestion), absence of tonic contraction between spasms, positive toxicology [2]
- Neuroleptic malignant syndrome: Altered mental status (unlike tetanus), very high CK, medication history [2]
- Stiff-person syndrome / PERM: Positive GAD/anti-glycine antibodies, altered mental status common [2]
- Hypocalcemic tetany: Low serum calcium, absence of trismus [2]
Key distinguishing feature of cephalic tetanus: Trismus + ipsilateral cranial nerve palsy (especially CN VII) + history of head/neck wound, with preserved consciousness. [2-3]
9. Past Medical History
- Vaccination history: Most critical element — number of doses, timing of last booster
- Prior tetanus episodes: Natural infection does not confer immunity [2]
- Diabetes, cardiovascular disease, immunosuppression: Associated with worse prognosis [1]
- Chronic otitis media: A recognized portal of entry for cephalic tetanus [1-2]
- Prior dental procedures or head/facial surgery
10. Physical Exam
- Vital signs: Tachycardia, hypertension (or labile BP), fever (if present, consider superinfection or autonomic dysfunction) [2]
- Head/face: Carefully examine the scalp for contaminated wounds (may be occult); look for risus sardonicus, eyelid retraction, eye deviation [1-2]
- CN exam: CN VII palsy (upper and lower face — both flaccid and spastic weakness can coexist); CN III, IV, VI palsies (eye deviation); CN XII (tongue deviation) [2-3]
- Jaw: Trismus — inability to open mouth; spatula test (touching the posterior pharyngeal wall with a spatula induces jaw spasm rather than gag reflex — reported sensitivity 94%, specificity 100%) [2]
- Neck: Rigidity, painful spasms
- Neurologic: Preserved consciousness, normal sensory exam, hyper-reflexia; no cerebellar signs [2]
- Respiratory: Assess for stridor, tachypnea, use of accessory muscles, oxygen saturation
11. Lab Studies
- Recommended initial labs: [1]
- CBC, electrolytes, BUN, creatinine
- Creatine kinase (CK) — elevated with rhabdomyolysis from sustained spasms
- CRP, procalcitonin — to assess for superinfection
- Calcium, magnesium — rule out hypocalcemic tetany
- Wound culture: Culture and Gram stain of debrided tissue (C. tetani is isolated in a minority of cases; a negative culture does not exclude tetanus) [2]
- Serum tetanus antibody levels: Rapid immunoassays can detect protective antibodies but lack standalone confirmatory utility; subprotective levels support the diagnosis [2][5]
- Toxicology screen: If strychnine poisoning is considered [2]
- Lumbar puncture: CSF is typically normal in tetanus; useful to exclude meningitis/encephalitis if diagnostic uncertainty [1]
12. Imaging
- CT head/face: Unremarkable in cephalic tetanus (no acute parenchymal abnormalities); useful to rule out stroke, abscess, or intracranial pathology [2-3]
- Gas locules: Presence of gas in soft tissue on CT could support a probable diagnosis [2]
- MRI brain: Normal in tetanus; may be needed to exclude brainstem stroke or demyelination
- Chest X-ray: Baseline and to evaluate for aspiration pneumonia
- Imaging is not diagnostic: Tetanus is a clinical diagnosis; imaging serves primarily to exclude mimics [2][7]
13. Special Tests
- Spatula test: Touching the posterior pharyngeal wall with a tongue depressor — a positive test (reflex jaw clamp) is highly specific for tetanus [2]
- Ablett classification: Grades severity from Grade 1 (mild) to Grade 4 (very severe with autonomic disturbance) [5]
- Tetanus Severity Score (TSS): Includes age, dyspnea at admission, time from first symptom to admission, comorbidities, entry site, blood pressure, and fever; sensitivity 77%, specificity 82% — outperforms Phillips and Dakar scores [1]
- Heart rate variability (HRV): Reduced HRV on ECG monitoring may indicate autonomic nervous system dysfunction before clinical signs are apparent [12]
- Electrophysiology: Can demonstrate dual peripheral (neuromuscular junction) and central (brainstem) sites of toxin action in cephalic tetanus [4]
14. ECG
- Indications: All patients with suspected tetanus should have continuous cardiac monitoring
- Findings associated with autonomic dysfunction: [8][13]
- Sinus tachycardia (most common)
- Bradycardia (alternating with tachycardia)
- ST-segment and T-wave changes (>93% of patients in one series had ≥1 ECG abnormality despite normal echocardiography) [13]
- QT prolongation
- Arrhythmias — ventricular and supraventricular
- Takotsubo cardiomyopathy: The most common cardiovascular event in tetanus (40% of all cardiovascular events); catecholamine-mediated; may present with ST elevation and wall motion abnormalities [1][8]
- Sudden cardiac arrest: Reported in 16% of cardiovascular events in tetanus [8]
15. Assessment
- Clinical summary: Cephalic tetanus is a rare, frequently misdiagnosed variant of localized tetanus presenting with trismus and cranial nerve palsies after head/neck injury. Both flaccid and spastic paralysis can coexist, reflecting dual peripheral and central toxin action. [2][4]
- Severity stratification: Use the Ablett classification and/or Tetanus Severity Score; however, even "mild" cephalic tetanus warrants ICU-level monitoring given the risk of rapid generalization and cardiorespiratory collapse [1-2]
- Typical vs atypical: Classic presentation is trismus + ipsilateral CN VII palsy after facial wound. Atypical presentations include fluctuating symptoms mimicking TIA, bilateral cranial nerve involvement, or isolated dysphagia [2]
- Complications: Generalization to full-body tetanus, laryngeal spasm, aspiration pneumonia, respiratory failure, autonomic dysfunction, Takotsubo cardiomyopathy, rhabdomyolysis with AKI, PRES, nosocomial infections, VTE [1]
16. Treatment Plan
Initial stabilization (ED):
- Secure the airway — have intubation equipment at bedside; early intubation if any signs of laryngeal spasm or respiratory compromise
- IV benzodiazepines for spasm control (diazepam 10–30 mg IV, titrate to effect) [1]
- Place patient in a quiet, dark, low-stimulation environment [1][7]
Specific therapy (Day 1): [1]
- HTIG 500 IU IM (single dose)
- Td or Tdap 0.5 mL IM (at a different anatomic site from HTIG)
- Metronidazole 500 mg IV q6h for 7–10 days
- Wound debridement — thorough exploration, removal of foreign bodies and devitalized tissue
ICU management: [1-2]
- Titrate benzodiazepines; add propofol or neuromuscular blocking agents (vecuronium) for refractory spasms
- Magnesium sulfate IV infusion for autonomic dysfunction and as adjunctive spasm control [14]
- Labetalol for sympathetic hyperactivity [1]
- Enteral feeding via NG tube or parenteral nutrition
- DVT prophylaxis with heparin [1]
- Bedside physical therapy when spasms allow [1]
Recovery phase: [1]
- Taper benzodiazepines over 14–21 days as spasms diminish
- Intensive physical therapy
- Psychotherapy support (prolonged ICU stays are psychologically traumatic)
- Administer second dose of Td/Tdap before discharge; complete full vaccination series (natural infection does not confer immunity) [2]
17. Disposition
- All suspected cephalic tetanus → ICU admission — even mild cases warrant ICU-level monitoring given the risk of rapid generalization and airway compromise [1-2]
- Admission criteria: Any patient with trismus + cranial nerve palsy + compatible wound history
- Observation is insufficient: Cephalic tetanus can progress to generalized tetanus with respiratory failure within hours [1-2]
- Specialist consultation: Infectious disease, critical care/intensivist, neurology (to help exclude mimics), surgery/ENT (wound debridement), and anesthesia (airway management)
- Discharge criteria: Resolution of spasms, stable autonomic function, ability to swallow safely, completion of initial vaccination, and arrangement for outpatient vaccination series completion [1]
18. Follow Up / Return Precautions
- Recovery timeline: Inhibitory neurotransmission takes 4–6 weeks to restore; median mechanical ventilation duration in severe cases is ~16 days; median hospital stay 22–30 days [2][11]
- Vaccination completion: Full primary series required post-discharge (natural infection does not confer immunity); administer additional Td/Tdap dose before discharge, then complete series per ACIP schedule [2][6]
- Follow-up timing: Infectious disease and primary care follow-up within 1–2 weeks of discharge
- Return precautions: Immediate return for new jaw stiffness, muscle spasms, difficulty breathing, difficulty swallowing, fever, or any neurological symptoms
- Long-term outcomes: Most survivors achieve good functional recovery — in one French cohort, 61% of ICU survivors had no lasting disability at ~4 years follow-up, even among elderly patients [2]
- Patient counseling: Emphasize that recovery is slow but most patients improve considerably with sustained supportive care; stress the critical importance of completing the vaccination series [2]
References
1. Tetanus. — Ergönül Ö, Kolsuz S, Figueroa JP. Lancet. 2026.
2. Tetanus. — Ergönül Ö, Kolsuz S, Figueroa JP. Lancet. 2026.
3. Tetanus. — Ergönül Ö, Kolsuz S, Figueroa JP. Lancet. 2026.
4. Tetanus: Recognition and Management. — Sudarshan R, Sayo AR, Renner DR, et al. The Lancet. Infectious Diseases. 2025.
5. Tetanus: Recognition and Management. — Sudarshan R, Sayo AR, Renner DR, et al. The Lancet. Infectious Diseases. 2025.
6. Teaching Video NeuroImages: Cephalic Tetanus: Not Every Facial Weakness Is Bell Palsy. — Nascimento FA, Hammoud N, Augusto FD. Neurology. 2019.
7. Teaching Video NeuroImages: Cephalic Tetanus: Not Every Facial Weakness Is Bell Palsy. — Nascimento FA, Hammoud N, Augusto FD. Neurology. 2019.
8. Facial Neuromuscular Junctions and Brainstem Nuclei Are the Target of Tetanus Neurotoxin in Cephalic Tetanus. — Fabris F, Varani S, Tonellato M, et al. JCI Insight. 2023.
9. Facial Neuromuscular Junctions and Brainstem Nuclei Are the Target of Tetanus Neurotoxin in Cephalic Tetanus. — Fabris F, Varani S, Tonellato M, et al. JCI Insight. 2023.
10. Tetanus. — Yen LM, Thwaites CL. Lancet. 2019.
11. Tetanus. — Yen LM, Thwaites CL. Lancet. 2019.
12. Prevention of Pertussis, Tetanus, and Diphtheria With Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP). — Liang JL, Tiwari T, Moro P, et al. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports. 2018.
13. Prevention of Pertussis, Tetanus, and Diphtheria With Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP). — Liang JL, Tiwari T, Moro P, et al. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports. 2018.
14. What Is Tetanus?. — Zhou S, Malani P. The Journal of the American Medical Association. 2026.
15. What Is Tetanus?. — Zhou S, Malani P. The Journal of the American Medical Association. 2026.
16. Magnitude, Patterns, and Associated Predictors of Cardiovascular Events in Tetanus: A 2-Year, Single-Center, Ambidirectional Cohort Study Involving 572 Patients. — Pham OKN, Tran BN, Duong MC, et al. Open Forum Infectious Diseases. 2023.
17. Magnitude, Patterns, and Associated Predictors of Cardiovascular Events in Tetanus: A 2-Year, Single-Center, Ambidirectional Cohort Study Involving 572 Patients. — Pham OKN, Tran BN, Duong MC, et al. Open Forum Infectious Diseases. 2023.
18. FDA Drug Label. — Updated date: 2010-10-28. Food and Drug Administration.
19. FDA Drug Label. — Updated date: 2010-10-28. Food and Drug Administration.
20. Tetanus Surveillance - United States, 2009-2023. — Hughes MM, Amin AB, Rubis AB. Morbidity and Mortality Weekly Report. Surveillance Summaries. 2026.
21. Tetanus Surveillance - United States, 2009-2023. — Hughes MM, Amin AB, Rubis AB. Morbidity and Mortality Weekly Report. Surveillance Summaries. 2026.
22. Management and Outcome of Adult Generalized Tetanus Patients in a Tertiary Hospital in Anhui, China: A Retrospective Study. — Huang J, Cai E, Ding W, et al. Frontiers in Public Health. 2025.
23. Management and Outcome of Adult Generalized Tetanus Patients in a Tertiary Hospital in Anhui, China: A Retrospective Study. — Huang J, Cai E, Ding W, et al. Frontiers in Public Health. 2025.
24. Heart Rate Variability as an Indicator of Autonomic Nervous System Disturbance in Tetanus. — Duong HTH, Tadesse GA, Nhat PTH, et al. The American Journal of Tropical Medicine and Hygiene. 2020.
25. Heart Rate Variability as an Indicator of Autonomic Nervous System Disturbance in Tetanus. — Duong HTH, Tadesse GA, Nhat PTH, et al. The American Journal of Tropical Medicine and Hygiene. 2020.
26. Maternal and Neonatal Tetanus. — Thwaites CL, Beeching NJ, Newton CR. Lancet. 2015.
27. Maternal and Neonatal Tetanus. — Thwaites CL, Beeching NJ, Newton CR. Lancet. 2015.
28. Magnesium Sulphate for Treatment of Severe Tetanus: A Randomised Controlled Trial. — Thwaites CL, Yen LM, Loan HT, et al. Lancet. 2006.
29. Magnesium Sulphate for Treatment of Severe Tetanus: A Randomised Controlled Trial. — Thwaites CL, Yen LM, Loan HT, et al. Lancet. 2006.